Compare SAMG & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | BSEM |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.0M | 76.9M |
| IPO Year | 2012 | 2026 |
| Metric | SAMG | BSEM |
|---|---|---|
| Price | $10.62 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.3K | ★ 159.4K |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.04 | $87.68 |
| P/E Ratio | $213.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.09 | $1.88 |
| 52 Week High | $16.16 | $5.44 |
| Indicator | SAMG | BSEM |
|---|---|---|
| Relative Strength Index (RSI) | 61.46 | 29.74 |
| Support Level | $10.68 | N/A |
| Resistance Level | $11.61 | $4.12 |
| Average True Range (ATR) | 0.37 | 0.32 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 77.14 | 9.91 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.